SG11201805442XA - Compositions and methods related to multimodal therapeutic cell systems for immune indications - Google Patents

Compositions and methods related to multimodal therapeutic cell systems for immune indications

Info

Publication number
SG11201805442XA
SG11201805442XA SG11201805442XA SG11201805442XA SG11201805442XA SG 11201805442X A SG11201805442X A SG 11201805442XA SG 11201805442X A SG11201805442X A SG 11201805442XA SG 11201805442X A SG11201805442X A SG 11201805442XA SG 11201805442X A SG11201805442X A SG 11201805442XA
Authority
SG
Singapore
Prior art keywords
international
rule
cambridge
multimodal
methods related
Prior art date
Application number
SG11201805442XA
Inventor
Avak Kahvejian
Jordi Mata-Fink
Robert Deans
Tiffany Chen
John Round
Noubar Afeyan
Nissen Torben Straight
Nathan Dowden
Tom Wickham
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of SG11201805442XA publication Critical patent/SG11201805442XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 11M1111101110101011111 HO 1111101110111011100110011101111111110111011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/123644 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 35/12 (2015.01) Cl 2N 5/10 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 35/18 (2015.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/013033 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 11 January 2017 (11.01.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/277,130 11 January 2016 (11.01.2016) US (84) Designated States (unless otherwise indicated, for every 62/359,448 7 July 2016 (07.07.2016) US kind of regional protection available): ARIPO (BW, GH, 62/370,915 4 August 2016 (04.08.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/420,973 11 November 2016 (11.11.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: RUBIUS THERAPEUTICS, INC. [US/US]; DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 620 Memorial Dr #100W, Cambridge, MA 02139 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: KAHVEJIAN, Avak; 1 Memorial Drive, 7th SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, _ Floor, Cambridge, MA 02142 (US). MATA-FINK, Jordi; GW, KM, ML, MR, NE, SN, TD, TG). — 8 Windsor Rd # 1, Somerville, MA 02144 (US). DEANS, Declarations under Rule 4.17: _ Robert, J.; 1609 Ramsgate Court, Riverside, CA 92506 — as to applicant's entitlement to apply for and be granted a (US). CHEN, Tiffany, F.; 91 Sidney St. Apt 207, Cam- 4.17(ii)) patent (Rule = bridge, MA 02139 ROUND, 1 Memorial (US). John; Drive, 7th Floor, Cambridge, MA 02142 AFEYAN, — as to the applicant's entitlement to claim the priority of the (US). Noubar, B.; 1 Sunset Ridge, Lexington, MA 02421 (US). earlier application (Rule 4.17(iii)) = STRAIGHT NISSEN, Torben; 68 Waban Hill Rd., Published: = Chestnut Hill, MA 02467 (US). DOWDEN, Nathan; 4 = — with international search report (Art. 21(3)) Goddu Ave., Winchester, MA 01890 (US). WICKHAM, = Tom; 20 Hickory Lane, Grodon, MA 01450 (US). —— before limit the expiration of the time for amending the to be in the event of receipt of (74) Agent: KOYFMAN, Hannah, R.; Lando & Anastasi, claims and republished LLP, Riverfront Office Park, One Main Street, Suite 1100, amendments (Rule 48.2(h)) = Cambridge, MA 02142 (US). — with sequence listing of description (Rule 5.2(a)) part = = = = = = 1-1 7r 7r cr) ei ,-1 IN 1-1 (54) Title: COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR IM- C:= ei MUNE INDICATIONS 0 (57) : The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune condi- tions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease.
SG11201805442XA 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications SG11201805442XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277130P 2016-01-11 2016-01-11
US201662359448P 2016-07-07 2016-07-07
US201662370915P 2016-08-04 2016-08-04
US201662420973P 2016-11-11 2016-11-11
PCT/US2017/013033 WO2017123644A1 (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications

Publications (1)

Publication Number Publication Date
SG11201805442XA true SG11201805442XA (en) 2018-07-30

Family

ID=57907000

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201805253SA SG11201805253SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201805442XA SG11201805442XA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG10202007639SA SG10202007639SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG10201913837TA SG10201913837TA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201805253SA SG11201805253SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202007639SA SG10202007639SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG10201913837TA SG10201913837TA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Country Status (22)

Country Link
US (8) US10456421B2 (en)
EP (3) EP3402492B1 (en)
JP (5) JP7093302B2 (en)
KR (2) KR20180095713A (en)
CN (3) CN108778298A (en)
AU (2) AU2017207736A1 (en)
BR (2) BR112018013853A2 (en)
CA (2) CA3010510A1 (en)
DK (1) DK3402491T3 (en)
ES (1) ES2907695T3 (en)
HK (1) HK1259079A1 (en)
HR (1) HRP20220147T1 (en)
HU (1) HUE057660T2 (en)
IL (2) IL260010A (en)
LT (1) LT3402491T (en)
MX (2) MX2018008514A (en)
PL (1) PL3402491T3 (en)
PT (1) PT3402491T (en)
RS (1) RS62939B1 (en)
SG (4) SG11201805253SA (en)
SI (1) SI3402491T1 (en)
WO (2) WO2017123646A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113337402A (en) 2011-10-17 2021-09-03 麻省理工学院 Intracellular delivery
CN105848793B (en) 2013-08-16 2019-03-05 麻省理工学院 Material selectivity is delivered to cell
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
EP3125927B1 (en) 2014-04-01 2021-01-27 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US11111472B2 (en) 2014-10-31 2021-09-07 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells
CN107002089B (en) 2014-11-14 2021-09-07 麻省理工学院 Disruption and field-effected delivery of compounds and compositions into cells
WO2016115179A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
JP6925984B2 (en) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー Delivery of substance to anucleated cells
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CN108778298A (en) 2016-01-11 2018-11-09 鲁比厄斯治疗法股份有限公司 Composition related with the multi-mode therapeutic cells system of immunological adaptation disease and method
EP3583202A1 (en) * 2017-02-17 2019-12-25 Rubius Therapeutics, Inc. Functionalized erythroid cells
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
KR20200037353A (en) 2017-08-07 2020-04-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 Platform for creating safe cell therapy products
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
JP2021500855A (en) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド Antigen-presenting polypeptides and how to use them
US20210187018A1 (en) * 2017-12-07 2021-06-24 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
SG11202005203UA (en) * 2017-12-23 2020-07-29 Rubius Therapeutics Inc Artificial antigen presenting cells and methods of use
RU2020132924A (en) * 2018-03-08 2022-04-11 Рубиус Терапьютикс, Инк. THERAPEUTIC CELL SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
KR20210024488A (en) * 2018-05-24 2021-03-05 러쉬 유니버시티 메디컬 센터 ICOSL for use as a kidney treatment
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
AU2020209941A1 (en) 2019-01-18 2021-07-22 Flagship Pioneering, Inc. TREM compositions and uses thereof
SG11202109073VA (en) * 2019-02-20 2021-09-29 Rubius Therapeutics Inc Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
CN113544269A (en) 2019-03-04 2021-10-22 旗舰创业创新第六有限责任公司 Cyclic polyribonucleotides and pharmaceutical compositions thereof
AU2020243436A1 (en) * 2019-03-18 2021-10-07 Bio-Rad Abd Serotec Gmbh Antigen binding fragments conjugated to a plurality of Fc isotypes and subclasses
KR20210142678A (en) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions comprising modified circular polyribonucleotides and uses thereof
EP3963092A1 (en) * 2019-05-02 2022-03-09 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
CN114269921A (en) 2019-05-31 2022-04-01 旗舰创业股份有限公司 Use of TREM compositions to modulate tRNA cells
AU2020292427A1 (en) 2019-06-14 2022-01-06 Flagship Pioneering Innovations Vi, Llc Circular RNAs for cellular therapy
WO2020257730A1 (en) 2019-06-19 2020-12-24 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
CN112195154B (en) * 2019-07-08 2024-03-29 江苏汇智生物科技有限公司 Cell for genetically modifying and expressing modified PLA2R receptor and application thereof
EP4025048A2 (en) 2019-09-05 2022-07-13 Hemanext Inc. Methods for the preservation of reagent red blood cells using carbon monoxide
CN114746545A (en) * 2019-10-18 2022-07-12 西湖生物医药科技(杭州)有限公司 Engineered erythrocytes using artificial MHC to present specific cancer neoantigens
EP4055169A1 (en) 2019-11-04 2022-09-14 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
WO2021092064A1 (en) 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Trem compositions for con-rare codons and related uses
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
EP4096715A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
TW202142689A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Compositions for translation and methods of use thereof
KR20220140542A (en) * 2020-02-07 2022-10-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 Methods and uses for bioengineered preparation of enucleated cells
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
JP2023526423A (en) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー Immunogenic compositions and uses thereof
EP4153224A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Coronavirus antigen compositions and their uses
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
CA3180101A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
WO2021262799A1 (en) 2020-06-23 2021-12-30 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
TW202241471A (en) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 Methods of increasing nkp30-positive lymphocytes in a subject and uses thereof
EP4297784A1 (en) * 2021-02-26 2024-01-03 Cytonus Therapeutics, Inc. Compositions and methods for therapeutic delivery
TW202304482A (en) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
JP2024512669A (en) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Tanotransmission polypeptides and their use in the treatment of cancer
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
CA3232635A1 (en) 2021-09-17 2023-03-23 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
CA3234817A1 (en) * 2021-10-12 2023-04-20 Remo MOOMIAIE Systems and methods for manufacturing of therapeutic cells
TW202322826A (en) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
TW202340461A (en) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
TW202342064A (en) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
WO2023230578A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
WO2023230573A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026290A1 (en) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US20020151004A1 (en) * 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2004087876A2 (en) * 2003-03-25 2004-10-14 Valeocyte Therapies Llc Use of red blood cells to facilitate cell activation
DE10335833A1 (en) * 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
FR2873925B1 (en) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions METHOD AND DEVICE FOR LYSE-RESCALING FOR THE INCORPORATION OF ACTIVE PRINCIPLE, IN PARTICULAR ASPARAGINASE OR INOSITOL HEXAPHOSPHATE, IN ERYTHROCYTES
FR2884717B1 (en) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions ERYTHROCYTES CONTAINING ARGININE DEIMINASE
PL1899364T3 (en) 2005-05-17 2020-08-24 University Of Connecticut Compositions and methods for immunomodulation in an organism
WO2007030708A2 (en) 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
US7462485B2 (en) 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
FR2919804B1 (en) 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
FR2925339B1 (en) 2007-12-24 2010-03-05 Erytech Pharma DRUG FOR THE TREATMENT OF PANCREATIC CANCER
EP2242507B1 (en) 2008-02-13 2013-02-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (en) 2008-03-10 2011-01-21 Erytech Pharma FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
FR2938332B1 (en) 2008-11-07 2011-11-25 Erytech Pharma PREDICTIVE TEST FOR NEUTRALIZATION OF ASPARAGINASE ACTIVITY
FR2944106B1 (en) 2009-04-03 2012-09-28 Erytech Pharma METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP).
EP2493487B1 (en) 2009-10-27 2016-08-24 Erytech Pharma Composition to induce specific immune tolerance
AU2011289579B2 (en) * 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
EP2825048A4 (en) 2012-03-13 2015-10-14 Anthrogenesis Corp Modified erythrocyte precursor cells and uses thereof
CN104394884A (en) 2012-03-21 2015-03-04 爱瑞泰克药物公司 Medicament for the treatment of acute myeloid leukemia (AML)
CN103224957B (en) 2013-04-16 2017-08-04 福建三一造血技术有限公司 The method of external evoked generation ASPase containing L II red blood cell medicine
FR3005420B1 (en) 2013-05-07 2015-09-18 Erytech Pharma METHOD OF STABILIZING SUSPENSIONS OF ERYTHROCYTES ENCAPSULATING AN ACTIVE INGREDIENT, SUSPENSIONS OBTAINED
US10471099B2 (en) 2013-05-10 2019-11-12 Whitehead Institute For Biomedical Research In vitro production of red blood cells with proteins comprising sortase recognition motifs
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (en) 2014-02-12 2018-05-18 Erytech Pharma PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
EP3125927B1 (en) 2014-04-01 2021-01-27 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
CN108778298A (en) 2016-01-11 2018-11-09 鲁比厄斯治疗法股份有限公司 Composition related with the multi-mode therapeutic cells system of immunological adaptation disease and method
BR112019000195A2 (en) 2016-07-07 2019-04-24 Rubius Therapeutics, Inc. compositions and methods related to therapeutic cellular systems expressing exogenous rna
KR20190091497A (en) * 2016-12-02 2019-08-06 루비우스 테라퓨틱스, 아이엔씨. Compositions and Methods Associated with Cellular Systems for Penetration into Solid Tumors
EP3583202A1 (en) 2017-02-17 2019-12-25 Rubius Therapeutics, Inc. Functionalized erythroid cells
WO2019040516A1 (en) 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
WO2019133881A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for enginerering erythroid cells

Also Published As

Publication number Publication date
CN115969987A (en) 2023-04-18
PL3402491T3 (en) 2022-04-19
DK3402491T3 (en) 2022-02-14
US10716811B2 (en) 2020-07-21
JP7093302B2 (en) 2022-06-29
CN108778298A (en) 2018-11-09
US20200016209A1 (en) 2020-01-16
AU2017207736A1 (en) 2018-07-12
US20220072048A1 (en) 2022-03-10
JP2021078519A (en) 2021-05-27
EP4019026A1 (en) 2022-06-29
EP3402491B1 (en) 2021-12-22
BR112018013853A2 (en) 2018-12-18
US20190083540A1 (en) 2019-03-21
JP2022171843A (en) 2022-11-11
SG10201913837TA (en) 2020-03-30
WO2017123644A1 (en) 2017-07-20
EP3402491A1 (en) 2018-11-21
CA3010510A1 (en) 2017-07-20
SI3402491T1 (en) 2022-05-31
JP2021112216A (en) 2021-08-05
HRP20220147T1 (en) 2022-04-15
SG11201805253SA (en) 2018-07-30
JP2019501655A (en) 2019-01-24
JP2019501654A (en) 2019-01-24
US20200129556A1 (en) 2020-04-30
IL260010A (en) 2018-07-31
LT3402491T (en) 2022-02-25
MX2018008514A (en) 2019-05-09
MX2018008515A (en) 2019-05-09
EP3402492A1 (en) 2018-11-21
US20230293588A1 (en) 2023-09-21
IL259991A (en) 2018-07-31
CN108697733A (en) 2018-10-23
BR112018013728A2 (en) 2018-12-18
HUE057660T2 (en) 2022-06-28
ES2907695T3 (en) 2022-04-26
US20180085402A1 (en) 2018-03-29
HK1259079A1 (en) 2019-11-22
US20180187155A1 (en) 2018-07-05
KR20180095713A (en) 2018-08-27
RS62939B1 (en) 2022-03-31
US20180193385A1 (en) 2018-07-12
PT3402491T (en) 2022-03-03
EP3402492B1 (en) 2022-11-16
SG10202007639SA (en) 2020-09-29
US10568910B2 (en) 2020-02-25
US10517897B1 (en) 2019-12-31
US10456421B2 (en) 2019-10-29
CA3009063A1 (en) 2017-07-20
WO2017123646A1 (en) 2017-07-20
KR20180095098A (en) 2018-08-24
AU2017207738A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
SG11201805442XA (en) Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201908391XA (en) Methods for modulating an immune response
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201901716TA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201804662PA (en) Image projection system
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201903450YA (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201805755SA (en) Methods of administering hepcidin
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases